QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
YouTube
Video
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Inhibikase Therapeutics
(NASDAQ:IKT)
0.68
-0.0186[-2.66%]
Last update: 9:57AM
15 minutes delayed
Day High/Low0.68 - 0.7
52 Week High/Low0.66 - 6.41
Open / Close0.7 / -
Float / Outstanding19.9M / 25.2M
Vol / Avg.6.8K / 94.3K
Mkt Cap17.2M
P/E-
50d Avg. Price1.21
Div / Yield-
Payout Ratio-
EPS-0.2
Total Float19.9M

Inhibikase Therapeutics (NASDAQ:IKT), Quotes and News Summary

Inhibikase Therapeutics (NASDAQ: IKT)

Day High/Low0.68 - 0.7
52 Week High/Low0.66 - 6.41
Open / Close0.7 / -
Float / Outstanding19.9M / 25.2M
Vol / Avg.6.8K / 94.3K
Mkt Cap17.2M
P/E-
50d Avg. Price1.21
Div / Yield-
Payout Ratio-
EPS-0.2
Total Float19.9M
Benzinga - 17 hours ago
Benzinga - Mar 31, 2022, 5:02PM
Benzinga - Mar 8, 2022, 8:04AM
Benzinga - Feb 7, 2022, 6:17AM
Benzinga - Jan 11, 2022, 12:08PM
Benzinga - Jan 5, 2022, 8:32AM
Benzinga - Nov 29, 2021, 8:07AM
Benzinga - Nov 15, 2021, 5:33PM
Benzinga - Oct 19, 2021, 8:07AM
Benzinga - Oct 4, 2021, 9:57AM
Benzinga - Oct 4, 2021, 8:11AM
Benzinga - Sep 23, 2021, 8:06AM
Benzinga - Aug 16, 2021, 4:48PM
Benzinga - Jul 26, 2021, 10:09AM
load more
Inhibikase Therapeutics Inc is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Its multi-therapeutic pipeline focuses on neurodegeneration and its lead program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to treat Parkinson's disease inside and outside the brain. The company is performing its Phase I, randomized single ascending dose and multiple ascending dose, study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. It is also advancing a novel drug delivery platform to treat certain forms of cancer at the same time as it is developing novel drugs for the treatment of neurodegenerative disease.
Read More

Earnings

see more
Q2 2022Est.ActualSurprise
EPS
(EXPECTED)2022-08-15
REV
Q1 2022Est.ActualSurprise
EPS-0.170-0.180 -0.0100
REV300.000K46.031K-253.969K

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Inhibikase Therapeutics Questions & Answers

Q
How do I buy Inhibikase Therapeutics (IKT) stock?
A

You can purchase shares of Inhibikase Therapeutics (NASDAQ: IKT) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are Inhibikase Therapeutics's (IKT) competitors?
A

There are no as such competitors for Inhibikase Therapeutics.

Q
What is the target price for Inhibikase Therapeutics (IKT) stock?
A

The latest price target for Inhibikase Therapeutics (NASDAQ: IKT) was reported by JonesTrading on Thursday, July 15, 2021. The analyst firm set a price target for 12.00 expecting IKT to rise to within 12 months (a possible 1664.71% upside). 1 analyst firms have reported ratings in the last year.

Q
Current Stock Price for Inhibikase Therapeutics (IKT)?
A

The stock price for Inhibikase Therapeutics (NASDAQ: IKT) is $0.68 last updated Today at May 17, 2022, 1:57 PM UTC.

Q
Does Inhibikase Therapeutics (IKT) pay a dividend?
A

There are no upcoming dividends for Inhibikase Therapeutics.

Q
When is Inhibikase Therapeutics (NASDAQ:IKT) reporting earnings?
A

Inhibikase Therapeutics’s Q2 earnings are confirmed for Monday, August 15, 2022.

Q
Is Inhibikase Therapeutics (IKT) going to split?
A

There is no upcoming split for Inhibikase Therapeutics.

Q
What sector and industry does Inhibikase Therapeutics (IKT) operate in?
A

Inhibikase Therapeutics is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.